Home / Market News / $MBRX

$MBRX news and market catalysts

The 13 most recent market catalysts affecting $MBRX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

13 catalysts 3 high impact 5 bullish 4 bearish Biotechnology
Nov 17, 2026 Corporate Catalyst Neutral Impact 75
Moleculin Biotech Reports Third Quarter 2026 Financial Results
Moleculin Biotech reported a net loss of $6.5 million for Q3 2026, a substantial improvement from $25.4 million in Q3 2025, primarily due to the absence of non-cash warrant liabili…
Nov 13, 2026 Corporate Catalyst Bullish Impact 55
Moleculin Biotech Secures Australian Patent for Annamycin Formulation Technology
Moleculin Biotech announced it has secured an Australian patent for its Annamycin formulation technology, specifically for the preparation of preliposomal Annamycin lyophilizate. T…
Nov 11, 2026 Corporate Catalyst Bullish Impact 65
Moleculin Biotech Announces Positive Preclinical Data for Annamycin in Pancreatic Cancer
Moleculin Biotech disclosed positive preclinical data for its drug candidate, Annamycin, in pancreatic cancer models. This is significant because it suggests a potential new therap…
Nov 7, 2026 Corporate Catalyst Neutral Impact 55
Moleculin Biotech, Inc. Schedules Q3 2026 Earnings Announcement
Moleculin Biotech, Inc. (MBRX) has scheduled its Q3 2026 earnings announcement for November 9, 2026, at 7:00 AM ET. This is a routine disclosure for publicly traded companies, prov…
Nov 5, 2026 Corporate Catalyst Neutral Impact 55
Moleculin Biotech Announces Acceptance of Annamycin Data for Presentation at 2026 ASH Annual Meeting
Moleculin Biotech announced the acceptance of Annamycin data for presentation at the 2026 ASH Annual Meeting. This is a positive development as it confirms the company will have a …
Oct 30, 2026 Corporate Catalyst Bullish Impact 65
Moleculin Biotech Completes Dosing in Part A of Pivotal MIRACLE Trial
Moleculin Biotech announced the completion of patient dosing for Part A of its pivotal Phase 2/3 MIRACLE trial for AnnAraC, a treatment for relapsed or refractory acute myeloid leu…
Oct 20, 2026 Corporate Catalyst Bullish Impact 85
Moleculin Biotech shares are trading higher after the company highlighted progress in its Phase 2/3 MIRACLE trial of Annamycin, including completed Part A enrollment and encouraging interim efficacy results.
This headline represents a significant positive corporate catalyst for Moleculin Biotech. Progress in a Phase 2/3 trial, especially with 'encouraging interim efficacy results,' de-…
Oct 16, 2026 Corporate Catalyst Bearish Impact 75
Moleculin Biotech shares are trading lower after the company announced a 1-for-20 reverse stock split, effective October 20.
A 1-for-20 reverse stock split for Moleculin Biotech (MBRX) is a significant corporate action, often undertaken by companies whose stock price has fallen to very low levels, riskin…
Oct 16, 2026 Corporate Catalyst Neutral Impact 65
Moleculin Biotech Announces 1-For-20 Reverse Stock Split, Effective October 20
Moleculin Biotech is executing a 1-for-20 reverse stock split, reducing its outstanding shares from approximately 20.9 million to 1.05 million. This move is often undertaken by com…
Sep 25, 2026 Corporate Catalyst Bullish Impact 75
Moleculin Biotech shares are trading higher after the company announced new preclinical data indicating that the antitumor activity of its lead drug candidate, Annamycin, in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity.
The announcement of positive preclinical data for Annamycin in pancreatic cancer is a strong positive catalyst for Moleculin Biotech. Pancreatic cancer is a notoriously difficult c…
Aug 14, 2026 Corporate Catalyst Bearish Impact 92
Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate
Moleculin Biotech (MBRX) announced Q2 earnings per share of $(1.40), which was a substantial miss compared to the analyst consensus estimate of $(1.01). This 38.61% deviation from …
Jul 31, 2026 Corporate Catalyst Bearish Impact 95
Moleculin Biotech Stock Is Sinking Friday: What's Going On?
Moleculin Biotech (MBRX) experienced a sharp decline in its stock price after announcing a $9.3 million public offering priced at a substantial discount (75 cents per share) compar…
Jul 31, 2026 Corporate Catalyst Bearish Impact 75
Moleculin Biotech shares are trading lower after the company announced it priced a $9.3 million public offering.
The announcement of a public offering, especially one of this size relative to the company's market capitalization, is a significant corporate catalyst. The primary impact is negat…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.